{"id":"guamecycline","rwe":[],"tags":[{"label":"guamecycline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"xanthomycin a","offLabel":[],"synonyms":["guamecycline","tetrabiguanide","Xanthomycin A","xantomicina"],"timeline":[],"approvals":[],"brandName":"Xanthomycin A","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"guamecycline","explanation":"Imagine your body's cells have locks on them, and Xanthomycin A is a key that fits into one of those locks. When it binds, it can either unlock or block the normal functioning of the cell, depending on the target and the specific effects of the drug. This can help to treat certain diseases by altering the behavior of cells in the body.","oneSentence":"Xanthomycin A is a small molecule that works by binding to a specific target, although the exact target is unknown.","technicalDetail":"Xanthomycin A's mechanism of action is not well understood, but it is believed to involve binding to a specific protein or receptor, potentially altering downstream signaling pathways and cellular behavior."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3273","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUAMECYCLINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:49:55.237514","biosimilars":[],"competitors":[],"genericName":"guamecycline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4NQR4R6G3S","CHEBI":"CHEBI:135854","INN_ID":"2705","UMLSCUI":"C0061935","ChEMBL_ID":"CHEMBL2008915","PUBCHEM_CID":"54688683","MESH_SUPPLEMENTAL_RECORD_UI":"C001312"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xanthomycin A, also known as guamecycline, is a small molecule drug of unknown target and class. Its development and current ownership are not specified, and it has not been approved by the FDA for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Xanthomycin A's commercial status, including patent status and generic availability, is unclear. As a result, key safety considerations and potential side effects are not well established.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}